EBS FY 2025 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena

EBSEmergent BioSolutions Inc.

$446M

FY 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$743M-28.8% YoY

Gross Profit

$351M47.2% margin

Operating Income

$110M14.8% margin

Net Income

$53M7.1% margin

EPS (Diluted)

$0.93

Cash Flow

Operating Cash Flow

$171M

Free Cash Flow

$157M

Stock-Based Comp.

$16M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$796M

Stockholders' Equity

$523M

Cash & Equivalents

$205M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$743M	$1.0B	-28.8%
Gross Profit	$351M	$375M	-6.6%
Operating Income	$110M	-$109M	+201.4%
Net Income	$53M	-$191M	+127.6%